May 8, 2020 / 12:06 PM / 16 days ago

BRIEF-Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University To Develop Novel Oligonucleotide Platform For The Treatment Of Genetically Driven Cancers

May 8 (Reuters) - Fortress Biotech Inc:

* FORTRESS BIOTECH ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH COLUMBIA UNIVERSITY TO DEVELOP NOVEL OLIGONUCLEOTIDE PLATFORM FOR THE TREATMENT OF GENETICALLY DRIVEN CANCERS

* FORTRESS BIOTECH INC - PLATFORM BEING EXPLORED AS A TREATMENT FOR CORONAVIRUSES, INCLUDING COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below